



CHIMERIC
THERAPEUTICS

THE ASX LEADER IN CELL THERAPY

**TRANSFORMATIVE
PORTFOLIO EXPANSION**

THE CORE-NK PLATFORM
A CLINICALLY VALIDATED, OFF THE SHELF
NATURAL KILLER CELL PLATFORM

CORE-NK Platform



Transformative Portfolio Expansion

A **platform technology** that can be leveraged to develop multiple new therapies

Triples Chimeric's pipeline adding **5 new cell therapy assets**

Extends Chimeric's clinical development program with **5 new clinical trials by 2023**


Broadens Chimeric's reach into **10+ disease areas** including blood cancers and solid tumours

Ability to further leverage the platform through **partnerships or licensing**


Propels Chimeric forward as the **ASX leader in cell therapy** and as an emerging global cell therapy company

CHIMERIC PIPELINE DEVELOPMENT STRATEGY

- 2 novel individualized (autologous) CAR T cell therapies
- Exploration of opportunities with alternative cell types and cell sources



WHY NATURAL KILLER (NK) CELLS?



Natural Killer (NK) Cell

Natural killer cells are superior immune cells


Natural killer cells are part of our immune system and have a natural ability to identify and kill tumour cells. (they're named for this "natural" killing ability)

Natural killer cells are also able to produce cytokines that recruit and activate the immune system to mount an additional response to kill tumour cells.

Natural killer cells also have fail-safe mechanisms that prevent the killing of healthy cells making them ideal for off the shelf platforms.

WHY OFF THE SHELF?

Off the shelf therapies offer benefits and convenience to individualized therapies



Healthier starting material

Scalable manufacturing with reduced costs

Rapidly available, off the shelf

Ability to reach more patients

Early Stage, Off the Shelf, NK Cell Platforms are Driving Significant Value



Ph. 1 non-engineered NK cell platform
Preclinical CAR NK products (2)

January 2021

Collaboration



\$30M USD upfront + up to \$1.8 B
in milestones and royalties for to
three CAR NK cell therapies
targeting solid tumours



Preclinical non-engineered
NK cell platform

June 2021

Collaboration



\$45M USD + undisclosed
milestones and royalties for up
to four NK cell therapies



Preclinical non-engineered
NK cell platform

June 2021

Collaboration




Undisclosed upfront + \$2.3B in
milestones and royalties for up
to three CAR NK cell therapies

Chimeric Therapeutics Off the Shelf, Natural Killer Cell Platform

CORE-NK Platform

Clinically Validated, Off the Shelf,
Robust, Enhanced, Natural Killer Cell Platform




INVESTMENT HIGHLIGHTS

CORE-NK PLATFORM


Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform

- An off the shelf, natural killer cell platform technology that will be leveraged to develop multiple new therapies
- Clinical validation of the platform with a complete Phase 1 clinical trial in blood cancers and solid tumours
- Platform enables near-term development of four additional Chimeric therapies for solid tumours and blood cancers
- Synergistic with existing Chimeric assets, providing the ideal foundation to fast-forward development of CLTX CAR-NK and CDH17 CAR-NK therapies
- Further ability to leverage the platform to build additional new therapies through partnerships or licensing
- Phase 1 trials for new assets planned to begin in 2023
- Off the shelf therapies and NK cells are highly attractive for investment and partnering
- Attractive option terms with a planned research collaboration with Case Western



THE CORE-NK PLATFORM

A Novel Strategy to Enhance NK Cells Natural Abilities



**David
WALD, MD, PhD**

Associate Professor, Department
of Pathology, School of Medicine
Member, Immune Oncology Program,
Case Comprehensive Cancer Center,
Associate Director for Basic Research, University
Hospitals, Wesley Center for Immunotherapy



Dr David Wald is a clinician-scientist at Case Western Reserve University in Cleveland, Ohio.

With an interest in cancer drug development Dr Wald has focused his research on using natural killer cells to eliminate colorectal cancer and acute myeloid leukemia.

Dr Wald developed a novel strategy to expand and activate NK cells ex vivo using a proprietary feeder cell line made him a CTP award recipient in 2018.

This engineered NK platform was specifically designed to overcome the hurdles often associated with NK cell development, including the ability to produce large numbers of highly active universal donor NK cells that maintain their activity once they're in the body.

CORE-NK Platform Cells

Enhancing the Natural Cancer-Fighting Power of NK cells

Natural Killer (NK) Cell



Natural killer cells are found in our bodies normally and are able to recognize and kill cancer cells- but are not robust and active enough to overcome cancer as it grows


ACTIVATION AND EXPANSION OF HEALTHY DONOR NAKED NATURAL KILLER CELLS

nature

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells

Evelyn D. Ojo¹, Ashish Arunkumar Sharma¹, Ruifu Liu¹, Stephen Moreton¹, Mary Ann Checkley-Luttge¹, Kalpana Gupta¹, Grace Lee¹, Dean A. Lee¹, Folashele Ogburne¹, Rafick-Pierre Sekaly¹, Marcelo de Lima¹ & David N. Brud^{1,2*}

CORE-NK Platform Cell



CORE-NK cells are made by activating and expanding natural killer cells to make them more active and robust in large quantities

CORE-NK PLATFORM

PHASE 1 CLINICAL TRIAL

PATIENT ELIGIBILITY

BLOOD CANCERS

Acute Myeloid Leukemia
Plasma Cell Myeloma
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Myeloproliferative Syndromes
Non-Hodgkin Lymphoma
Hodgkin Lymphoma

SOLID TUMOURS


Adenocarcinoma of the Rectum
Rhabdomyosarcoma
Soft Tissue Sarcoma
Ewing's Sarcoma
Colon Cancer

Phase 1 Clinical Trial

Dr David Wald, Case Comprehensive
Cancer Center


Study Initiation: May 2018
Primary Completion: June 2021
Estimated Study Completion: May 2022

PHASE 1 DOSE ESCALATION



CORE-NK PLATFORM (CHM 0201)


PHASE 1 CLINICAL TRIAL COMPLETE



DATA ANTICIPATED 2022

CORE-NK PLATFORM (CHM 0201)

WHAT DO WE DO WITH IT?



1.

Next Generation CORE-NK Platform

Further enhance the CORE-NK platform with next generation technologies for development as a combination therapy

2.

CAR-NK Products

Fast-forward development of supercharged CAR NK products using our CLTX and CDH17 chimeric antigen receptors


3.

Leverage the CORE-NK Platform

Identify collaborations or licensing opportunities to further expand the utilization of the CORE-NK platform

CORE-NK PLATFORM (CHM 0201)

WHAT DO WE DO WITH IT?



1. Next Generation CORE-NK Platform
2. CAR-NK Products
3. Leverage the CORE-NK Platform


1.

NEXT GENERATION CORE-NK Platform

Further enhancing the cancer-fighting power of the CORE-NK platform cells



Next Generation Enhancements



CHM 0301 NEXT GENERATION CORE-NK Platform

Development in Blood Cancers as Combination Therapy

Acute Myeloid Leukemia

- Cancer of the bone marrow and blood that generally progresses at a rapid pace
- Incidence 4.3/ 100,000
- 2nd most common type of leukemia with ~100,000 new cases globally each year
- 5 year survival 24%

B Cell Malignancies

- Type of non-Hodgkin lymphoma that originates in the B cells
- Incidence 8/ 100,000
- 85% of all non-Hodgkin lymphomas; includes diffuse large B cell lymphoma & follicular lymphoma
- 5 year survival ~69%

Multiple Myeloma


- Cancer of the plasma cells in the bone marrow
- Blood cancer of cells found in the bone marrow, specifically the "plasma cells."
- Incidence: 5/ 100,000
- 5 year survival ~54%

2.

CAR-NK PRODUCTS

HOW DO YOU TURN A CORE-NK CELL INTO A CAR-NK?


CORE-NK Platform Cell



CAR-NK products are made by inserting Chimeric Antigen Receptors (CARs) into the CORE-NK platform cells




CAR-NK Cell



The Chimeric Antigen Receptor then gets expressed on the cell surface supercharging the cells cancer fighting abilities

CHIMERIC SUPERCHARGED CAR-NK PRODUCTS

LEVERAGING OUR CHIMERIC ANTIGEN RECEPTORS




TRANSFORMATIVE PORTFOLIO DEVELOPMENT

A DIVERSIFIED PIPELINE WITH CUTTING EDGE INNOVATION

Novel Design

T Cells

Autologous (personal)



NK Cells






Allogeneic (off-the-shelf)



3.

LEVERAGE THE CORE-NK PLATFORM

IDENTIFY COLLABORATION AND LICENSING OPPORTUNITIES

	<p>Development of 4 CAR NK / CAR T products</p>	<p>\$50M upfront + \$50M equity investment + \$3B milestones + double digit royalties</p>
	<p>Development of 3 CAR NK products</p>	<p>\$30M upfront + \$612/ per CAR NK; \$1.8B potential</p>
	<p>Development of 2 CAR iNKT products</p>	<p>Undisclosed upfront + \$875M USD milestones + royalties</p>
	<p>Development of 4 CAR NK products</p>	<p>Undisclosed upfront, milestones and royalties</p>
	<p>Non-engineered NK cells</p>	<p>Acquired by Sanofi \$308 M EUROS</p>

CORE-NK PLATFORM DEVELOPMENT PLAN

4 NEW CLINICAL TRIALS BY 2023

- ✓ CORE-NK platform Phase 1 clinical trial completed at Case Western
- Initiate development of the Next Generation CORE-NK platform



- Development of CLTX CAR-NK and CDH17 CAR-NK products
- Identification of 3rd undisclosed CAR for development

- Phase 1 clinical trial: Next generation CORE-NK platform
- Phase 1 CAR NK clinical trial (CLTX CAR-NK, CDH17 CAR-NK and undisclosed CAR-NK)



ESTABLISHING VALUE IN THE NK DEVELOPMENT FIELD


Planned Time to Phase 1 Clinical Trial

Company	Market Cap	2021	2022	2023
	\$90M AUS	CHM 0201 (CORE- NK)		
		CHM 0301 (Next Generation CORE-NK)		
		CHM 1301 (CLTX CAR-NK)		
		CHM 2301 (CDH17 CAR-NK)		
		CHM 3301 (Undisclosed CAR-NK)		
	\$948M USD	CD19		
		CD19+ CD79		
		CD133+ EGFR		
	\$5.0B USD	CD19		
		BCMA		
		MICA A/B		
		B7H3		
	\$851M USD	Enhanced NK Cells		
		HER2		
	\$540M USD	NKG2D		
		CD19		
		CD70		
	\$637M USD	Agent 797		
		BCMA		
		Stromal Target		


Market cap as of Nov 29/ 2021

THE MOST EXPERIENCED CELL THERAPY TEAM IN AUSTRALIA

GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION



Jennifer CHOW
Chief Operating Officer



- **KITE PHARMA**
Head of Global Marketing, Commercial Operations and Analytics
- **CELGENE**
Global Cell Therapy Commercial Lead



Dr Syed RIZVI
Chief Medical Officer



- **LEGEND BIOTECH**
VP, Clinical Development and Medical Affairs
- **CELGENE**
Global Cell Therapy Medical Affairs Lead



Dr Eliot BOURK
VP, Business and Corporate Development



- **KITE PHARMA**
Head of Early Commercial Development
- **CELGENE**
Global Cell Therapy Commercial Strategy and Next Generation Platforms



Dr Li REN
VP, Technical Operations



- **BMS**
Global Manufacturing, Cell Therapy Development and Operations
- **CELGENE**
CAR T CMC and Technology Development

Development of over

25 CELL THERAPIES

including

4/5 OF THE FDA-APPROVED CAR T CELL THERAPIES



The ASX Leader in Cell Therapy & an Emerging Global Cell Therapy Company

The CORE-NK Platform

A clinically validated, off the shelf NK platform technology that can be leveraged to develop multiple new therapies

Studied in a phase 1 clinical trial completed in June 2021 in both solid tumours and blood cancers

Enables the accelerated development of 4 Chimeric next generation, off the shelf NK and CAR-NK products

Additional opportunity for further development through internal development and/ or partnerships



Cutting edge cell therapy portfolio with 7 innovative assets using alternative cell types and sources

Advanced clinical development with 4 clinical trials by 2022 and 8 clinical programs by 2023

Broad development in 10+ disease areas including solid tumours and blood cancers

Propels Chimeric forward as the ASX leader in cell therapy and as an emerging global cell therapy company

Transforming Chimeric Therapeutics



CHIMERIC
THERAPEUTICS

CONTACT INFORMATION

Jennifer Chow

Chief Executive Officer
and Managing Director
Cell: +1 908-723-8387
jchow@chimerictherapeutics.com

Paul Hopper

Executive Chairman
Cell: +61 406 671 515
paulhopper@lifescienceportfolio.com